A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
T cell immunity directed against tumor-encoded amino acid substitutions occurs in some melanoma patients. This implicates missense mutations as a source of patient-specific neoantigens. However, a systematic evaluation of these putative neoantigens as targets of antitumor immunity is lacking. Moreover, it remains unknown whether vaccination can augment such responses. We found that a dendritic cell vaccine led to an increase in naturally occurring neoantigen-specific immunity and revealed previously undetected human leukocyte antigen (HLA) class I-restricted neoantigens in patients with advanced melanoma. The presentation of neoantigens by HLA-A*02:01 in human melanoma was confirmed by mass spectrometry. Vaccination promoted a diverse neoantigen-specific T cell receptor (TCR) repertoire in terms of both TCR-β usage and clonal composition. Our results demonstrate that vaccination directed at tumor-encoded amino acid substitutions broadens the antigenic breadth and clonal diversity of antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Vaccines have been used as an approach to enhance anti-tumor immune responses and have demonstrated encouraging results in preclinical and clinical studies, leading to an expansion of the intratumoral T cell infiltration and anti-tumor immune responses (Carreno et al., 2015; Ott et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Carreno et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Flicek, P., Amode, M. R., Barrell, D., Beal, K., Billis, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fitzgerald, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1196 · Cited by 1,214
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Reliable prediction of T‐cell epitopes using neural networks with novel sequence representations
Nielsen, M., Lundegaard, C., Worning, P., Lauemøller, S. L., Lamberth, K., Buus, S., Brunak, S., & Lund, O. (2003) · Protein Science · doi:10.1110/ps.0239403 · Cited by 1,074
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Cited by
Items 601–700 of 1,003
New trends in antitumor vaccines in melanoma
Vásquez, M., Tenesaca, S., & Berraondo, P. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.09.09 · Cited by 30
High-Throughput, Fast, and Sensitive Immunopeptidomics Sample Processing for Mass Spectrometry
Marino, F., Chong, C., Michaux, J., & Bassani‐Sternberg, M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-8979-9_5 · Cited by 30
Personal Neoantigen Vaccines for the Treatment of Cancer
Shetty, K. S., & Ott, P. A. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-060820-111701 · Cited by 30
Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor–Based Cellular Therapy
Martinov, T., & Greenberg, P. D. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061521-082114 · Cited by 30
Dai, J., Fang, L., Wang, X., Hua, J., Tu, Y., Li, S., He, K., Hang, L., Xu, Y., Jin, F., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202417871 · Cited by 30
Hasegawa, K., Ikeda, Y., Kunugi, Y., Kurosaki, A., Imai, Y., Kohyama, S., Nagao, S., Kozawa, E., Yoshida, K., Tsunoda, T., et al. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000214 · Cited by 30
Durgeau, A., Virk, Y., Gros, G., Voilin, E., Corgnac, S., Djenidi, F., Salmon, J., Adam, J., de Montpréville, V., Validire, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07603-1 · Cited by 30
Neoepitopes-based vaccines: challenges and perspectives
Alcazer, V., Bonaventura, P., Tonon, L., Valsesia‐Wittmann, S., Caux, C., & Depil, S. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.011 · Cited by 30
Galati, D., Zanotta, S., Bocchino, M., Filippi, R. D., & Pinto, A. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02805-3 · Cited by 30
Dendritic cell vaccination in melanoma patients: From promising results to future perspectives
Boudewijns, S., Bloemendal, M., Gerritsen, W. R., de Vries, I. J. M., & Schreibelt, G. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1197453 · Cited by 30
Jia, L., Hong, Y., He, X., Zhou, Y., Ren, L., Du, H., Zhao, B., Qin, B., Yang, Z., & Gao, D. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.109957 · Cited by 29
PIKfyve, expressed by CD11c-positive cells, controls tumor immunity
Choi, J. E., Qiao, Y., Kryczek, I., Yu, J., Gurkan, J. K., Bao, Y., Gondal, M. N., Tien, J. C.-Y., Maj, T., Yazdani, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48931-9 · Cited by 29
Song, Y., Li, H., Yuan, Y., Zhang, D., Wang, Z., Qi, B., Jiang, P., & Yu, A. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113612 · Cited by 29
An Immunological Glance on Pancreatic Ductal Adenocarcinoma
Melzer, M. K., Arnold, F., Stifter, K., Zengerling, F., Azoitei, N., Seufferlein, T. T. W., Bolenz, C., & Kleger, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093345 · Cited by 29
Golonka, R. M., & Vijay–Kumar, M. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.10.004 · Cited by 29
Manczinger, M., Koncz, B., Balogh, G. M., Papp, B. T., Asztalos, L., Kemény, L. V., Papp, B., & Pál, C. (2021) · Nature Cancer · doi:10.1038/s43018-021-00226-4 · Cited by 29
Vaccinating against cancer: getting to prime time
Chang, R., Gulley, J. L., & Fong, L. H. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006628 · Cited by 29
Cancer vaccines: from an immunology perspective
Makker, S., Galley, C., & Bennett, C. L. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad030 · Cited by 29
Veatch, J. R., Singhi, N., Srivastava, S., Szeto, J. L., Jesernig, B. L., Stull, S. M., Fitzgibbon, M., Sarvothama, M., Yechan-Gunja, S., James, S. E., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci144195 · Cited by 29
Yu, Z., Liu, W., He, Y., Sun, M., Yu, J., Jiao, X., Han, Q., Tang, H., Zhang, B., Xian, Y., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01081-7 · Cited by 29
Saxena, M., Marron, T. U., Kodysh, J., Finnigan, J. P., Onkar, S., Kaminska, A., Tuballes, K., Guo, R., Sabado, R. L., Meseck, M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0934 · Cited by 28
Harnessing Bacterial Membrane Components for Tumor Vaccines: Strategies and Perspectives
Bai, Z., Wang, X., Liang, T., Xu, G., Cai, J., Xu, W., Yang, K., Hu, L. T., & Pei, P. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401615 · Cited by 28
Dao, T., Korontsvit, T., Zakhaleva, V., Jarvis, C. A., Mondello, P., Oh, C. Y., & Scheinberg, D. A. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1252895 · Cited by 28
Empirical and Rational Design of T Cell Receptor-Based Immunotherapies
Jones, H. F., Molvi, Z., Klatt, M. G., Dao, T., & Scheinberg, D. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.585385 · Cited by 29
Dao, T., Mun, S. S., Molvi, Z., Korontsvit, T., Klatt, M. G., Khan, A. G., Nyakatura, E. K., Pohl, M. A., White, T. E., Balderes, P. J., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.151624 · Cited by 28
Short open reading frame genes in innate immunity: from discovery to characterization
Malekos, E., & Carpenter, S. B. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.07.005 · Cited by 28
Dillman, R. O., Nistor, G. I., & Keirstead, H. S. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2198467 · Cited by 28
LENS: Landscape of Effective Neoantigens Software
Vensko, S. P., II, Olsen, K. S., Bortone, D. S., Smith, C. C., Chai, S., Beckabir, W., Fini, M., Jadi, O., Rubinsteyn, A., & Vincent, B. G. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad322 · Cited by 28
Deciphering tumor-infiltrating dendritic cells in the single-cell era
Huang, Q., Wang, F., Di, H., Li, X., Li, X., Lei, T., Yue, J., & Liu, C. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00459-2 · Cited by 29
Personalized Dendritic-cell-based Vaccines Targeting Cancer Neoantigens
Kamigaki, T., Takimoto, R., Okada, S., Ibe, H., Oguma, E., & Goto, S. (2024) · Anticancer Research · doi:10.21873/anticanres.17196 · Cited by 28
Zolkind, P., Dunn, G. P., Lin, T., Griffith, M., Griffith, O. L., & Uppaluri, R. (2016) · Oral Oncology · doi:10.1016/j.oraloncology.2016.09.010 · Cited by 28
Vaccinations for Colorectal Cancer: Progress, Strategies, and Novel Adjuvants
Jiang, S., Good, D. M., & Wei, M. Q. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143403 · Cited by 28
Vroman, H. H., Balzaretti, G., Belderbos, R. A., Klarenbeek, P. L., van Nimwegen, M., Bezemer, K., Cornelissen, R., Niewold, I. T. G., van Schaik, B. D. C., van Kampen, A. H., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000251 · Cited by 28
Hao, Q., Long, Y., Yang, Y., Deng, Y., Ding, Z., Yang, L., Shu, Y., & Xu, H. (2024) · Vaccines · doi:10.3390/vaccines12070717 · Cited by 27
Chen, C., Zhou, Q., Wu, R., Li, B., Chen, Q., Zhang, X., & Shi, C. (2019) · BioMed Research International · doi:10.1155/2019/2183510 · Cited by 27
Lione, L., Salvatori, E., Petrazzuolo, A., Massacci, A., Maggio, R., Conforti, A., Compagnone, M., Aurisicchio, L., Ciliberto, G., & Palombo, F. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1898832 · Cited by 27
Prognostic and Immunological Role of Gasdermin E in Pan-Cancer Analysis
Zhang, Z., Zhao, S., Yang, H., Chen, Y., Feng, H., An, M., & Chen, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.706266 · Cited by 27
Beyond Sequencing: Prioritizing and Delivering Neoantigens for Cancer Vaccines
Roesler, A. S., & Anderson, K. S. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1884-4_35 · Cited by 27
Boudewijns, S., Koornstra, R. H. T., Westdorp, H., Schreibelt, G., van den Eertwegh, A. J. M., Foppen, M. H. G., Haanen, J. B. A. G., de Vries, I. J. M., Figdor, C. G., Bol, K. F., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1201625 · Cited by 27
Cancer Immunogenomics: Computational Neoantigen Identification and Vaccine Design
Hundal, J., Miller, C. A., Griffith, M., Griffith, O. L., Walker, J., Kiwala, S., Graubert, A., McMichael, J. F., Coffman, A. C., & Mardis, E. R. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030726 · Cited by 27
Self-citationOyarce, C., Cruz, S. R., Gálvez‐Cancino, F., Vargas, P., Moreau, H. D., Díaz‐Valdivia, N., Díaz, J., Salazar‐Onfray, F., Pacheco, R., Lennon‐Duménil, A., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01794 · Cited by 27
Duan, X., Chan, C., & Lin, W. (2018) · Angewandte Chemie · doi:10.1002/ange.201804882 · Cited by 27
Ushering in Integrated T Cell Repertoire Profiling in Cancer
Jiang, N. J., Schonnesen, A. A., & Ma, K.-Y. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.11.005 · Cited by 27
Leick, K. M., Pinczewski, J., Mauldin, I. S., Young, S. J., Deacon, D. H., Woods, A. N., Bosenberg, M., Engelhard, V. H., & Slingluff, C. L. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02345-5 · Cited by 27
Bai, P., Li, Y., Zhou, Q., Xia, J., Wei, P., Deng, H., Wu, M., Chan, S. K., Kappler, J. W., Zhou, Y., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1868130 · Cited by 27
Bauzá‐Martinez, J., Heck, A. J. R., & Wu, W. (2021) · Communications Biology · doi:10.1038/s42003-021-02364-y · Cited by 27
Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma
Geskin, L. J., Damiano, J. J., Patrone, C. C., Butterfield, L. H., Kirkwood, J. M., & Falo, L. D. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000441 · Cited by 27
Sarkizova, S., & Hacohen, N. (2017) · Nature · doi:10.1038/d41586-017-07267-9 · Cited by 27
Saba, N. F., Wong, S. J., Nasti, T. H., McCook‐Veal, A. A., McDonald, M. W., Stokes, W. A., Anderson, A., Ekpenyong, A., Rupji, M., Abousaud, M. I., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.1143 · Cited by 26
Advances in Cell and Immune Therapies for Melanoma
Timis, T., Buruiana, S., Dima, D. M., Nistor, M., Mureșan, X. M., Cenariu, D., Țigu, A. B., & Tomuleasa, C. (2025) · Biomedicines · doi:10.3390/biomedicines13010098 · Cited by 26
Reticker-Flynn, N. E., & Engleman, E. G. (2020) · eLife · doi:10.7554/elife.53839 · Cited by 26
He, X., Zhou, S., Dolan, M., Shi, Y., Wang, J., Quinn, B., Jahagirdar, D., Huang, W., Tsuji, M., Пили, Р., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003101 · Cited by 26
Boosting Antitumor Immunity with an Expanded Neoepitope Landscape
Nagel, R., Pataskar, A., Champagne, J., & Agami, R. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1525 · Cited by 26
Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic
Fenton, G. A., & Mitchell, D. A. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2257 · Cited by 26
Cuevas, M. V. R., Hardy, M., Larouche, J., Apavaloaei, A., Kina, E., Vincent, K., Gendron, P., Laverdure, J., Durette, C., Thibault, P., et al. (2023) · Genome biology · doi:10.1186/s13059-023-03029-1 · Cited by 26
Abascal, J. W., Oh, M. S., Liclican, E. L., Dubinett, S. M., Salehi‐Rad, R., & Liu, B. (2023) · Cells · doi:10.3390/cells12192404 · Cited by 26
Chattopadhyay, S., Hazra, R., Mallick, A., Gayen, S., & Roy, S. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189170 · Cited by 26
Immunotherapy in atypical teratoid-rhabdoid tumors: Data from a survey of the HGG-Immuno Group
Gool, S. V., Holm, S., Rachor, J., Adamson, L., Technau, A., Maass, E., Frühwald, M. C., Schlegel, P. G., & Eyrich, M. K. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.06.004 · Cited by 26
Hematologic neoplasms: Dendritic cells vaccines in motion
Galati, D., & Zanotta, S. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.08.016 · Cited by 26
Ex vivo dendritic cell generation—A critical comparison of current approaches
Han, P., Hanlon, D. J., Sobolev, O., Chaudhury, R., & Edelson, R. L. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.10.003 · Cited by 26
Yuan, C., Xiang, L., Cao, K., Zhang, J., Luo, Y., Sun, W., Zhang, N., Ren, J., Zhang, J., Gong, Y. Q., et al. (2020) · Aging · doi:10.18632/aging.102917 · Cited by 26
Bommireddy, R., Muñoz, L. E., Kumari, A., Huang, L., Fan, Y., Monterroza, L., Pack, C. D., Ramachandiran, S., Reddy, S. J. C., Kim, J., et al. (2020) · Vaccines · doi:10.3390/vaccines8020182 · Cited by 26
Immunogenomics in personalized cancer treatments
Kiyotani, K., Toyoshima, Y., & Nakamura, Y. (2021) · Journal of Human Genetics · doi:10.1038/s10038-021-00950-w · Cited by 26
Advances in Neoantigen-Based Cancer Vaccines
Wu, A.-C., Nakamura, Y., & Kiyotani, K. (2025) · Cancers · doi:10.3390/cancers18010144 · Cited by 25
Barroso‐Sousa, R., & Ott, P. A. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0738-2 · Cited by 25
Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer
Aparicio, B., Repáraz, D., Ruiz, M., Llópiz, D., Silva, L., Vercher, E., Theunissen, P., Tamayo, I., Smerdou, C., Igea, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.985886 · Cited by 25
DNA based neoepitope vaccination induces tumor control in syngeneic mouse models
Viborg, N., Pavlidis, M. A., Barrio-Calvo, M., Friis, S., Trolle, T., Sørensen, A. B., Thygesen, C. B., Kofoed, S. V., Kleine‐Kohlbrecher, D., Hadrup, S. R., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00671-5 · Cited by 25
Functionalized nanoparticles crossing the brain–blood barrier to target glioma cells
Wu, Y., Qian, Y., Peng, W., & Qi, X. (2023) · PeerJ · doi:10.7717/peerj.15571 · Cited by 25
Weng, J., Zheng, G., Wen, J., Yang, J., Yang, Q., Zheng, X., & Yan, Q. (2023) · Drug Delivery · doi:10.1080/10717544.2023.2232950 · Cited by 25
Mu, S., Chen, L., Dong, H., Li, S., Zhang, Y., Yin, S., Tian, Y., Ding, Y., Sun, S., Shang, S., et al. (2024) · Journal of Virology · doi:10.1128/jvi.02002-23 · Cited by 25
Immunotherapy in the Precision Medicine Era: Melanoma and Beyond
Su, M. Y., & Fisher, D. E. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002196 · Cited by 25
Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma
Nielsen, J. S., Chang, A., Wick, D. A., Sedgwick, C. G., Zong, Z., Mungall, A. J. J., Martin, S. D., Kinloch, N. N., Ott-Langer, S., Brumme, Z. L., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1321184 · Cited by 25
Yang, P., Song, H., Feng, Z., Wang, C., Huang, P., Zhang, C., Kong, D., & Wang, W. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900010 · Cited by 25
Recent progress in supramolecular peptide assemblies as virus mimics for cancer immunotherapy
Cai, Y., Wei, R., Zhai, Y., Wang, J., Zheng, C., Li, Y., & Zhang, P. (2019) · Biomaterials Science · doi:10.1039/c9bm01380f · Cited by 25
Matsushita, H., Hasegawa, K., Oda, K., Yamamoto, S., Asada, K., Karasaki, T., Yabuno, A., Nishijima, A., Nejo, T., Kobayashi, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000375 · Cited by 25
Song, N., Guo, H., Ren, J., Hao, S., & Wang, X. (2018) · Oncology Letters · doi:10.3892/ol.2018.8188 · Cited by 25
Bassani‐Sternberg, M., Chong, C., Guillaume, P., Solleder, M., Pak, H., Gannon, P. O., Kandalaft, L. E., Coukos, G., & Gfeller, D. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/098780 · Cited by 25
Progress in cancer vaccines enabled by nanotechnology
Kim, B., Abdelfattah, N. S., Hostetler, A., & Irvine, D. J. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-02021-z · Cited by 24
Sabado, R. L., Meseck, M. L., & Bhardwaj, N. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3387-7_44 · Cited by 24
Identification of immunotherapeutic targets by genomic profiling of rectal NET metastases
Koşaloğlu‐Yalçın, Z., Zörnig, I., Halama, N., Kaiser, I., Buchhalter, I., Grabe, N., Eils, R., Schlesner, M., Califano, A., & Jäger, D. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1213931 · Cited by 24
Mature Dendritic Cells May Promote High-Avidity Tuning of Vaccine T Cell Responses
Kumbhari, A., Egelston, C. A., Lee, P. P., & Kim, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584680 · Cited by 24
Repáraz, D., Aparicio, B., Llópiz, D., Hervás‐Stubbs, S., & Sarobe, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042022 · Cited by 24
Adoptive Cellular Therapy (ACT) for Cancer Treatment
Yang, F., Jin, H., Wang, J., Sun, Q., Yan, C., Wei, F., & Ren, X. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-7555-7_4 · Cited by 25
Informatics for cancer immunotherapy
Hammerbacher, J., & Snyder, A. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx682 · Cited by 24
Jiang, D., Xi, B., Tan, W., Chen, Z., Wei, J., Hu, M., Lu, X., Chen, D., Cai, H., & Du, H. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae547 · Cited by 23
“…including long-peptide vaccines, RNA vaccines, and dendritic cell vaccines, as well as adoptive cell therapy with neoantigen-reactive T cells, have shown efficacy in inducing tumor rejection (Gubin et al. 2014, Carreno et al. 2015, Sahin et al. 2017, Keskin et al. 2019, Kristensen et al. 2022).”
BackgroundNovel paradigm of therapeutic intervention for skin cancer: challenges and opportunities
Nasim, M., Khan, M., Parveen, R., Gull, A., Khan, S. M., & Ali, J. (2024) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-024-00686-2 · Cited by 23
The Roles of Alternative Splicing in Tumor-immune Cell Interactions
Wang, Y., Zhang, H., Jiao, B., Nie, J., Li, X., Wang, W., & Wang, H. (2020) · Current Cancer Drug Targets · doi:10.2174/1568009620666200619123725 · Cited by 23
Schmitt, S., Tahk, S., Lohner, A., Hänel, G., Maiser, A., Hauke, M., Patel, L., Rothe, M., Josenhans, C., Leonhardt, H., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.602802 · Cited by 23
Zhang, H., Qin, G., Yu, H., Han, X., & Zhu, S. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02807-1 · Cited by 23
Reshaping Intratumoral Mononuclear Phagocytes with Antibody‐Opsonized Immunometabolic Nanoparticles
Liu, C., Zhou, Y., Guo, D., Huang, Y., Ji, X., Li, Q., Chen, N., Fan, C., & Song, H. (2023) · Advanced Science · doi:10.1002/advs.202303298 · Cited by 23
Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma
Ramirez, C. A., Becker‐Hapak, M., Singhal, K., Russler‐Germain, D. A., Frenkel, F. E., Barnell, E. K., McClain, E. D., Desai, S., Schappe, T., Onyeador, O. C., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2022007792 · Cited by 23
Self-citationBoudewijns, S., Bol, K. F., Schreibelt, G., Westdorp, H., Textor, J. C., van Rossum, M. M., Scharenborg, N. M., de Boer, A. J., van de Rakt, M. W. M. M., Pots, J. M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1191732 · Cited by 23
Immuno-oncology from the perspective of somatic evolution
González, S., Volkova, N. V., Beer, P. A., & Gerstung, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.001 · Cited by 23
Neoepitope targets of tumour-infiltrating lymphocytes from patients with pancreatic cancer
Meng, Q., Valentini, D., Rao, M., Moro, C. F., Paraschoudi, G., Jäger, E., Dodoo, E., Rangelova, E. B., Chiaro, M. D., & Maeurer, M. J. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0262-z · Cited by 23
In situ Vaccination by Direct Dendritic Cell Inoculation: The Coming of Age of an Old Idea?
Castiello, L., Aricò, E., D'Agostino, G., Santodonato, L., & Belardelli, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02303 · Cited by 23
Xin, G., Khatun, A., Topchyan, P., Zander, R., Volberding, P. J., Chen, Y., Shen, J., Fu, C., Jiang, A., See, W. A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0251 · Cited by 23
Faiena, I., Comín-Anduix, B., Berent-Maoz, B., Bot, A. I., Zomorodian, N., Sachdeva, A., Said, J. W., Cheung-Lau, G. C., Pang, J., Macabali, M. H., et al. (2020) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000336 · Cited by 23
Combination therapies utilizing neoepitope-targeted vaccines
Lee, K. L., Schlom, J., & Hamilton, D. H. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02729-y · Cited by 23
Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories
Mizuno, S., Yamaguchi, R., Hasegawa, T., Hayashi, S., Fujita, M., Zhang, F., Koh, Y., Lee, S.-Y., Yoon, S., Shimizu, E., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95287-x · Cited by 23
Zhong, X., Li, C., Zhao, G., Li, M., Chen, S., Cao, Y., Wang, Q., Sun, J., Zhu, S., & Chang, S. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01682-5 · Cited by 23
Metadata
- Authors
- Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., & Linette, G. P.
- Affiliations
- Washington University in St. Louis (US)
- Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
- University of Oklahoma Health Sciences Center (US)
- MilliporeSigma (United States) (US)
- Corresponding author
- Carreno, Beatriz M.
- ORCID
- Venue
- Science
- Published
- 2015-05-15
- Volume
- 348
- Issue
- 6236
- Pages
- 803-808
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4549796
- OpenAlex
- W2007026865
- Cited by
- 1,285
- References
- 37
- Citations by year
- 2026: 45 · 2025: 90 · 2024: 104 · 2023: 108 · 2022: 126 · 2021: 159 · 2020: 135 · 2019: 138 · 2018: 124 · 2017: 118 · 2016: 99 · 2015: 38
- FWCI
- 62.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Human Genome Research Institute (5U54HG00307)
- National Cancer Institute (P30 CA91842, R21 CA179695)
- Barnes-Jewish Hospital Foundation
- Siteman Cancer Frontier Fund
- Our Mark on Melanoma (MOM) Foundation
- Come Out Swinging (COS) Foundation
- Blackout Melanoma Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- dendritic cell vaccine, melanoma, neoantigens, missense mutations, T cell receptor repertoire, HLA-A*0201, T cell-mediated antitumor immunity, clonal diversity, cancer immunotherapy
- MeSH terms
- Antigens, Neoplasm, Dendritic Cells, Humans, Melanoma, Mutation, Skin Neoplasms, T-Lymphocytes, Monitoring, Immunologic, HLA-A2 Antigen, Immunotherapy, Active, Receptors, Antigen, T-Cell, alpha-beta, Antigen Presentation, Cancer Vaccines, Amino Acid Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.